I recall the heavily oversubscribed placement in Oct 2013 by Peleton Capital on PAA’s behalf.
Given progress since, a capital raising of perhaps $3m should be well received.
Perhaps a temporary dilution but stakes are high and significant SP upside on continued good results.
FDA approval the ultimate goal and suspect they’re being extra careful with trials compliance.
I recall the heavily oversubscribed placement in Oct 2013 by...
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.5¢ |
Change
-0.020(8.51%) |
Mkt cap ! $85.12M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 23.5¢ | 21.0¢ | $190.1K | 865.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 207209 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.5¢ | 108846 | 1 |
View Market Depth
| Last trade - 13.44pm 06/06/2024 (20 minute delay) ? |
|
|||||
|
Last
21.5¢ |
Change
-0.020 ( 6.52 %) |
||||
| Open | High | Low | Volume | ||
| 22.5¢ | 23.0¢ | 21.0¢ | 289970 | ||
| Last updated 14.10pm 06/06/2024 ? | |||||
| PAA (ASX) Chart |